Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial
Neoadjuvant camrelizumab plus chemotherapy is effective for locally advanced, resectable ESCC, eliciting profound immune response that closely associated with clinical outcomes.
Authors
- Zhenyu Ding (ORCID: https://orcid.org/0000-0002-9545-8844)
- Yu‐Shang Yang (ORCID: https://orcid.org/0000-0001-5100-2266)
- Xuelei Ma (ORCID: https://orcid.org/0000-0002-9148-5001)
- Jiangfang Tian
- Zhen Lin
- Qing Hao (ORCID: https://orcid.org/0000-0002-1097-893X)
- Panpan Lin
- Peipei Wang
- Li Yang (ORCID: https://orcid.org/0000-0002-7880-2113)
- Shi H (ORCID: https://orcid.org/0000-0002-9958-9892)
- Heng Xu (ORCID: https://orcid.org/0000-0002-7748-2621)
- Yang Hu (ORCID: https://orcid.org/0000-0001-5900-7432)
- Ting Liu (ORCID: https://orcid.org/0000-0001-7870-3783)
- Yueyun Chen
- Yue Zheng
- Yong Yuan (ORCID: https://orcid.org/0009-0006-6518-974X)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Guangzhou First People's Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1038/s41416-024-02805-5
- Citations
- 15
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.59
Funders
- Sichuan University
- West China Hospital, Sichuan University